Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 46

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 46
---
. Miller led global regulatory strategic activities for commercial and development programs at Elan. Before that she worked at Allergan Medical, where she held various regulatory roles of increasing responsibility. Over her 20-year career, Dr. Miller has worked on all stages of drug development providing global regulatory strategic leadership and has led negotiation with EMA, FDA and International Regulatory Agencies across a range of therapeutic areas. Dr. Miller holds a BSc and PhD in Biotechnology from Dublin City University . Aziz Sawaf, CFA , has served as our Senior President, Chief Financial Officer since January 2023. Previously, Mr. Sawaf was our Vice President of Finance and a member of the Senior Leadership Team from October 2021 to December 2022, having joined us in June 2014 and serving in various roles of increasing responsibility across the finance organization. Prior to Theravance Biopharma, Mr. Sawaf spent four years at Gilead Sciences, working in several Finance roles supporting the Commercial and R&D organizations.

29

TABLE OF CONTENTS Prior to Gilead Sciences, Mr. Sawaf worked at Amgen, in Consulting and in internet start-up Finance. Mr. Sawaf holds a B.A. in Business Administration, Finance, from the University of Arizona, an M.B.A. from the University of Southern California Marshall School of Business, and a Master of Biotechnology Enterprise and Entrepreneurship (M.B.E.E.) from Johns Hopkins University. Mr. Sawaf has been a CFA Charterholder since 2013, and has served as a Board Member of the California Life Sciences Association (CLS) since 2023 where he is also a member of its Finance and Development Committees. 30

TABLE OF CONTENTS

EXECUTIVE COMPENSATION 2024 Summary Compensation Table The following table sets forth all of the compensation awarded to, earned by, or paid to our “principal executive officer” and our next two most highly compensated executive officers for our fiscal years ended December 31, 2024, and 2023, as applicable.

| Name and Principal Position                                            | ​ | ​ | Year |   |      |   | ​ | ​ | Salary($)(1) |   |           |   | ​ | ​ | Bonus($)(2) |   |       |   | ​ | ​ | ShareAwards($)(3) |   |           |   | ​ | ​ | Non-EquityIncentivePlanCompensation($)(4) |   |         |